Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon and painful digital ulcers. SSc-related pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis underlie a high mortality rate. This report covers the complex array of treatments used to treat the disease; ILD and skin fibrosis are targeted with systemic immunosuppressants, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, ACE inhibitors, and off-label biologics. We provide needed context for emerging players seeking to capitalize on the unmet needs in this underserved population.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Boehringer Ingelheim, Roche, GlaxoSmithKline, Bayer HealthCare, AbbVie
Key drugs: Ofev, Esbriet, Rituxan and biosimilars, Adempas, calcium channel blockers, conventional oral immunosuppressants, corticosteroids, PDE-5 inhibitors, select biologics
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.